Delaware Physician Genetic Testing Settlement: A Signed Plan for Results Never Used

In the Delaware physician genetic testing settlement, an internal medicine physician agreed to pay $180,000 to resolve False Claims Act allegations over unnecessary Medicare tests. Her approvals in the MySpecialistMD portal put her electronic signature on consultation certificates, test orders and medical-necessity documents. In the settlement’s admitted facts, she acknowledged that she never examined the beneficiaries or used their results to make treatment decisions. The paperwork described a course of care that the signing physician never provided.

The Department of Justice announced the settlement on April 29, 2026. The United States brought the civil case against the physician over orders made from April 4 through November 14, 2019. The agreement puts the portal’s role in concrete terms: the physician’s decisions followed company-supplied criteria, and her approval produced signed test orders.

What the Genetic Testing Settlement Covers

The signed agreement covers the physician’s genetic-testing referrals during that period and includes an admitted statement of facts. It identifies 103 Medicare beneficiaries referred to her through MySpecialistMD, where she worked as a contracted doctor.

The government’s complaint alleged that laboratories billed Medicare over $1.7 million for the ordered tests. Medicare paid $564,986, according to the admitted facts. The smaller settlement obligation belongs to the physician who supplied the orders. The case follows the clinician’s signatures into claims that someone else billed.

How MySpecialistMD Portal Approvals Became Signed Orders

The physician admitted that approving a consultation caused MySpecialistMD to apply her electronic signature and physician information to a series of genetic-testing documents. The approval supplied more than permission to run a test. It produced consultation certificates, order forms and supporting certifications of medical necessity.

The government’s complaint describes the workflow from the provider’s screen. A video tutorial showed providers a queue of consultations, patient intake forms and suggested diagnostic codes. Providers could enter a SOAP note recording the patient’s reported concerns, observations, assessment and plan. Approval then generated the beneficiary’s Medicare information, the ordering physician’s information and the electronic signature on the forms sent to laboratories.

According to the complaint, those forms made several representations at once. Consultation certificates said the physician had evaluated the patient. Laboratory requisitions said the testing was medically necessary, that the physician was authorized to order it and that the patient had consented. They also said the results would guide medical management and treatment decisions. Letters addressed to insurance claim specialists requested coverage on the same basis.

The government alleged that MySpecialistMD’s founder supplied stock clinical language for the notes. It made testing appear to be something the beneficiary requested and the treating provider ordered as part of a plan for managing care. A laboratory receiving the resulting paperwork would see a clinical explanation backed by a physician’s signature.

The complaint also quotes the physician’s own description of how the approvals had worked:

The distinction matters to anyone who has worked in a review queue. Reviewing the attached forms was the task the physician described. The documents generated afterward said she had evaluated a patient and would use the test results in that patient’s care.

The Results Never Became Treatment

The physician admitted that she had no pre-existing physician-patient relationship with the beneficiaries, did not examine them and made no effort to determine whether testing was medically necessary or consistent with Medicare coverage limits. She also admitted that she never reviewed or discussed the results with them and never used the results to manage their conditions or inform treatment.

Her determinations rested solely on MySpecialistMD’s criteria, rather than medical judgment consistent with Medicare requirements. That admission gives the case its point: the system produced medical-necessity documents without the physician making the medical-necessity assessment those documents represented.

The result matters because the test was supposed to inform care. The Medicare next-generation sequencing policy in force during these orders tied national coverage to a treating physician’s order and required results to reach that physician in a report specifying treatment options.

The complaint’s account of follow-up shows the practical gap. It alleged that beneficiaries could not contact the signing physician directly about their results. They had to go back through MySpecialistMD. Meanwhile, the physician’s signed letters had represented that she would receive the results and use them to pursue care.

A Wrong Number Became a Consultation Certificate

The government alleged that the physician approved testing for one beneficiary even after reaching the wrong telephone number. Her own clinical note recorded the failed contact. The resulting consultation certificate nevertheless said she had evaluated the beneficiary and planned testing to help manage the patient’s care.

The same order generated laboratory paperwork asserting medical necessity and patient consent. It also generated a letter asking Medicare to cover the testing. The attempted call and the signed documents told incompatible stories about the same patient.

This was part of a broader allegation about contact. The complaint said the physician initially ordered tests without speaking to beneficiaries, then continued approving orders after unsuccessful attempts to reach them. It described a later instruction from the company’s founder to approve testing only after speaking with the patient.

For an insider, the failed call is useful because the discrepancy sits inside the business’s own records. The note records what happened during the attempted consultation. The forms describe the clinical work used to support payment. Both belong to the same transaction.

The Physician’s Fee and the Laboratory’s Claim

The government alleged that MySpecialistMD paid approximately $25 for each purported consultation. The complaint puts her total payments from the company in 2019 at approximately $15,000. The physician did not bill Medicare for the genetic testing, according to the complaint. Laboratories used the resulting orders and supporting documents to perform tests and seek reimbursement.

The complaint identifies Landmark Diagnostics, a Houston clinical laboratory, as the company that processed approximately 76 percent of the tests and billed Medicare for them.

That separation is part of how an order-producing telemedicine business works. The HHS Office of Inspector General’s July 2022 special alert describes arrangements in which companies recruit patients and practitioners, pay practitioners for orders and transfer those orders to downstream buyers. It flags insufficient clinical information and arrangements with little prospect of follow-up. The clinician’s payer and the laboratory’s payer can be different parties.

Here, the government’s case followed the signed representations into the laboratory claims. The physician’s consultation fee described what she received for her work. Medicare’s payment described what the resulting tests cost the program. A small payment at the signing stage can enable a much larger claim downstream.

That is why the records surrounding an order matter to people beyond the billing department. A clinician sees the intake material and approval screen. Platform staff see how an approval becomes a set of forms. Laboratory staff see the documents accompanying the test and the claim. Each sees a different part of the same path to Medicare’s money.

What Evidence Is Needed to Prove Fraud?

We examine, with the insider who knows the work, how what the physician actually did compares with what the signed documents said and the laboratory billed. For genetic-test orders like these, that means connecting the intake material, clinical notes, approval history, generated forms, test results and claims.

An operations employee may know which clinical statements the platform inserted automatically. A clinician may know what information was available when an order was approved. A laboratory employee may know which signed documents supported reimbursement and where results were sent.

The 2024 Rutgers University Law Review article Plausible Cause: Connecting the FCA and AKS in the Context of Health Care Fraud describes how health care fraud can be hidden within large organizations and across complicated paperwork. This case makes that observation concrete. The clinical note, generated certificate and laboratory claim each described a different stage of the transaction. Read together, they show the difference between the consultation recorded and the care certified.

An insider’s knowledge gives those documents their meaning. Knowing how the software applied a signature, who supplied the clinical wording or what happened to the results can explain a discrepancy that the final claim alone would not show.

How Much of a Settlement Does a Whistleblower Get?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. For someone inside a genetic-testing operation, we assess the orders, certifications and claims with the insider who knows how they were produced.

You Know What the Approval Really Meant

If you know how a portal turned limited patient contact into signed medical-necessity documents, speak to one of our whistleblower experts about the orders you saw. We bring in healthcare fraud whistleblower lawyers who understand genetic-testing orders and Medicare claims, and work with you to build your strongest whistleblower case. Your knowledge of what the portal certified stays central as we pursue the case with you.